SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPENDENCE REFRACTORY TO ERYTHROPOIETIN THERAPY

被引：0
|
作者：
Jonasova, A. [1 ]
Minarik, L. [1 ]
Stopka, T. [2 ]
Sotakova, S. [1 ]
Polackova, H. [1 ]
Zemanova, Z. [3 ]
机构：
[1] Gen Univ Hosp, Dept Med 2, Prague, Czech Republic
[2] Gen Univ Hosp Biocev, Prague, Czech Republic
[3] Charles Univ Gen Hosp, Ctr Oncocytogen, Inst Biochem, Prague, Czech Republic
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P130
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First Single-Center Experience with Luspatercept Therapy in Low-Risk Myelodysplastic Syndrome (LR-MDS) Patients with Transfusion Dependence Refractory to Erythropoietin Therapy
    Jonasova, Anna
    Minarik, Lubomir
    Zemanova, Zuzana
    Polackova, Helena
    Stopka, Tomas
    BLOOD, 2022, 140 : 12311 - 12312
  • [2] RATIONALE FOR THERAPY DISCONTINUATION IN PATIENTS WITH LOWER-RISK TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES (LR-MDS)
    Gerds, A. T.
    Gupta, S.
    Sekeres, M. A.
    Nazha, A.
    Carraway, H. E.
    Hawthorne, S.
    King-Concialdi, K.
    McGuire, M.
    LEUKEMIA RESEARCH, 2017, 55 : S140 - S141
  • [3] Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Of cardiovascular Events and Death
    Fernandez de Gatta, Marta Alonso
    Martin Garcia, Ana
    Lopez Cadenas, Felix
    Pelaez Elena, Diaz
    Jimenez, Tamara
    Maria Hernandez-Rivas, Jesus
    Vallejo Garcia, Victor
    Barreiro Perez, Manuel
    Rodriguez Estevez, Lucia
    Castro Garay, Juan Carlos
    Avila, Diego
    Cabanillas Cabral, Adolfo Alejandro
    Sanchez Pablo, Clara
    Diez-Campelo, Maria
    Sanchez Fernandez, Pedro Luis
    BLOOD, 2019, 134
  • [4] Evaluation of Red Blood Cell Metabolism in Patients with Low-Risk Myelodysplastic Syndrome (LR-MDS): A Proof-ofConcept Study
    Fattizzo, Bruno
    Vercellati, Cristina
    Marcello, Anna
    Bortolotti, Marta
    Zaninoni, Anna
    Fermo, Elisa
    Bianchi, Paola
    Barcellini, Wilma
    BLOOD, 2022, 140 : 4016 - 4017
  • [5] Sustained Erythroid Response Associated With Red Cell Transfusion and Progressive Growth Factor Independence Is Feasible With Adjuvant Sertraline In Low-Risk Myelodysplastic Syndrome (LR-MDS)
    Li, Rui
    Zheng, Matthew
    Yellapragada, Sarvari Venkata
    Perez, Ruben Hernandez
    Mims, Martha
    Rivero, Gustavo A.
    BLOOD, 2013, 122 (21)
  • [6] Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study
    Zeidan, Amer M.
    Garcia-Manero, Guillermo
    DeZern, Amy E.
    Fenaux, Pierre
    Greenberg, Peter L.
    Savona, Michael R.
    Jurcic, Joseph G.
    Verma, Amit
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Laadem, Abderrahmane
    Zhang, Jennie
    Rampersad, Anita
    Sinsimer, Daniel
    Louis, Chrystal U.
    Linde, Peter G.
    Platzbecker, Uwe
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S318 - S319
  • [7] Luspatercept in patients with low-risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts (RS): long-term efficacy and safety data from the phase 3 MEDALIST study
    Platzbecker, U.
    Santini, V
    Komrokji, R. S.
    Zeidan, A.
    Garcia-Manero, G.
    Buckstein, R.
    Miteva, D.
    Keeperman, K.
    Holot, N.
    Zhang, J.
    Nadal, J. A.
    Rosettani, B.
    Yucel, A.
    Fenaux, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 134 - 134
  • [8] Improved Quality of Life upon Shifting from Darbepoetin to Luspatercept in Patients with Low-Risk Myelodysplastic Syndrome (MDS)
    Almomen, Abdulkareem Mohammed
    Dwaima, Mohammed Eid
    Akkad, Hadeel Bashir
    Owaidah, Tarek M.
    BLOOD, 2023, 142
  • [9] Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting
    Mukherjee, Sudipto
    Brown-Bickerstaff, Cherrishe
    Falkenstein, Angelica
    Makinde, Adeola Y.
    Bland, Emily
    Laney, JaLyna
    Garretson, Marne Prime
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Benefit of Continuing Luspatercept Therapy in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Did Not Achieve Red Blood Cell Transfusion Independence (RBC-TI) by Week 25 in the MEDALIST Study
    Platzbecker, Uwe
    Germing, Ulrich
    Fenaux, Pierre
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Tang, Derek
    Ito, Rodrigo
    Fabre, Shannon
    Mantovani, Emily
    Zhang, George
    Ha, Xianwei
    Miteva, Dimana
    Hughes, Christina
    Khan, Wasiulla
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 143
12345